Sparsentan
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Sparsentan |
| DrugBank ID | DB12548 |
| Brand Names (EU) | Filspari |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 94.52% |
Approved Indication (EMA)
Filspari is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion > 1.0 g/day (or urine protein-to-creatinine ratio > 0.75 g/g, see section 5.1).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | alopecia | 94.52% | DL |
| 2 | congenital hypotrichosis milia | 94.46% | DL |
| 3 | hypotrichosis simplex of the scalp | 94.32% | DL |
| 4 | diffuse alopecia areata | 94.22% | DL |
| 5 | angioedema | 93.01% | DL |
| 6 | lichen disease | 92.95% | DL |
| 7 | dermatitis | 91.78% | DL |
| 8 | potassium deficiency disease | 91.68% | DL |
| 9 | pulmonary arteriovenous malformation (disease) | 91.20% | DL |
| 10 | fetal erythroblastosis | 91.15% | DL |
| 11 | open-angle glaucoma | 91.10% | DL |
| 12 | lichen planus pemphigoides | 91.03% | DL |
| 13 | pulmonary arterial hypertension | 91.00% | DL |
| 14 | hypertrophic lichen planus | 90.92% | DL |
| 15 | annular atrophic lichen planus | 90.92% | DL |
| 16 | lichen planus pigmentosus | 90.92% | DL |
| 17 | primary hereditary glaucoma | 90.31% | DL |
| 18 | amyopathic dermatomyositis | 89.72% | DL |
| 19 | acrodermatitis chronica atrophicans | 89.71% | DL |
| 20 | psoriasis | 89.70% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.